In many cases, a provider may consider changing the route or protocol if clinically appropriate
On the other hand, common neurological diseases, e.g., Alzheimers disease have pronounced both marked sex-dependency (Ferretti et al., 2018) and involvement in the BBB decline (Zenaro et al., 2017)
1 Weight loss results: Tirzepatide: approximately 12% body weight loss from baseline Dulaglutide 1.5 mg: approximately 5% body weight loss from baseline Difference: roughly 7 percentage points in favour of tirzepatide Blood sugar control: Tirzepatide: -1.73% HbA1c reduction Dulaglutide 1.5 mg: -0.90% HbA1c reduction Difference: approximately 0.83 percentage points in favour of tirzepatide Cardiovascular outcomes Both medications have demonstrated cardiovascular safety and benefit in people with type 2 diabetes
The 20 mg/mL dosing chart shows that the 15 mg maximum dose requires only 75 units instead of 150
Clearly NALT isnt as superior as weve been led to believe, but why is that
The full Phase 3 programme, called TRIUMPH, is still running